New dual peroxisome proliferator activated receptor agonist —Saroglitazar in diabetic dyslipidemia and non-alcoholic fatty liver disease: integrated analysis of the real world evidence

Saroglitazar, a novel dual peroxisome proliferator activated receptor (PPAR) agonist, in clinical trials, has shown an improvement in lipid and glycemic parameters through the PPAR- α and γ agonist actions, res...

Source: Cardiovascular Diabetology - June 17, 2019 Category: Cardiology Authors: Upendra Kaul, Deven Parmar, K. Manjunath, Mitesh Shah, Krupi Parmar, Kishor P. Patil and Ashok Jaiswal Tags: Review Source Type: research